Total Liabilities for Biogen (BIIB)
According to Biogen's latest reported financial statements, the company's latest reported total liabilities is $11.18B USD. Total liabilities sum everything the company owes at the end of each reporting period — accounts payable, accrued expenses, debt, lease obligations, and other claims — as filed on the balance sheet. Compare with total assets and net assets for solvency context.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
BIIB
Currently viewingTotal LiabilitiesSwitch metric
Latest period
$11.18B
YoY change
-1.3%
5Y CAGR
-4.3%
Peak year (2020)
$13.93B
Latest annual
$11.18B
Total Liabilities history chart for Biogen (BIIB) from 1985 to 2025
Total Liabilities history table for Biogen (BIIB) from 1985 to 2025
| Fiscal year | Period ended | Reported | Total Liabilities | YoY |
|---|---|---|---|---|
| 2025 | $11.18B | -1.3% | ||
| 2024 | $11.33B | -5.9% | ||
| 2023 | $12.05B | +7.9% | ||
| 2022 | $11.17B | -13.6% | ||
| 2021 | $12.92B | -7.3% | ||
| 2020 | $13.93B | +0.3% | ||
| 2019 | $13.90B | +13.4% | ||
| 2018 | $12.26B | +10.9% | ||
| 2017 | $11.05B | +2.8% | ||
| 2016 | $10.75B | +6.1% | ||
| 2015 | $10.13B | +189.2% | ||
| 2014 | $3.50B | +8.0% | ||
| 2013 | $3.24B | +2.4% | ||
| 2012 | $3.17B | +20.7% | ||
| 2011 | $2.62B | -0.8% | ||
| 2010 | $2.64B | +15.4% | ||
| 2009 | $2.29B | -14.3% | ||
| 2008 | $2.67B | -13.6% | ||
| 2007 | $3.09B | +120.6% | ||
| 2006 | $1.40B | -4.0% | ||
| 2005 | $1.46B | -37.5% | ||
| 2004 | $2.34B | -4.5% | ||
| 2003 | $2.45B | +495.4% | ||
| 2002 | $411.57M | +10.6% | ||
| 2001 | $372.21M | +14.4% | ||
| 2000 | $325.45M | +9.1% | ||
| 1999 | $298.44M | +44.8% | ||
| 1998 | $206.10M | -25.7% | ||
| 1997 | $277.53M | +84.8% | ||
| 1996 | $150.20M | +74.2% | ||
| 1995 | $86.22M | +79.9% | ||
| 1994 | $47.93M | +50.7% | ||
| 1993 | $31.80M | +21.4% | ||
| 1992 | $26.20M | +85.8% | ||
| 1991 | $14.10M | +10.2% | ||
| 1990 | $12.80M | +113.3% | ||
| 1989 | $6.00M | -53.5% | ||
| 1988 | $12.90M | +0.8% | ||
| 1987 | $12.80M | +10.3% | ||
| 1986 | $11.60M | +6.4% | ||
| 1985 | $10.90M | — |
Total Liabilities values are taken from Biogen's reported balance sheets (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
Biogen (BIIB) most recent annual total liabilities stands at $11.18B (2025) – edged down 1.3% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Biogen total liabilities compounded at -4.3% per year, with a net decline across the window.
$13.93B stands as the all-time-high annual total liabilities, posted in 2020, against a low of $6.00M during 1989.
Among 8 Healthcare peers, Biogen (BIIB) ranks 9th; the peer median for total liabilities is $101.80B.
Biogen Total Liabilities by Year
Biogen Total Liabilities 2025: $11.18B
Biogen total liabilities in 2025 was $11.18B, edged down 1.3% below 2024.
Biogen Total Liabilities 2024: $11.33B
Biogen total liabilities in 2024 was $11.33B, declined 5.9% below 2023.
Biogen Total Liabilities 2023: $12.05B
Biogen total liabilities in 2023 was $12.05B, grew 7.9% from 2022.
Biogen Total Liabilities 2022: $11.17B
Biogen total liabilities in 2022 was $11.17B, declined 13.6% below 2021.
Biogen Total Liabilities 2021: $12.92B
Biogen total liabilities in 2021 was $12.92B.
See more financial history for Biogen (BIIB).
Sector peers — Total Liabilities
Companies in the same sector as Biogen, ranked by their latest total liabilities.
| Company | Total Liabilities | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $348.86B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $207.88B | Healthcare |
| AbbVie Inc. (ABBV) | $137.19B | Healthcare |
| Johnson & Johnson (JNJ) | $117.67B | Healthcare |
| Eli Lilly and Company (LLY) | $85.94B | Healthcare |
| Merck & Co., Inc. (MRK) | $84.20B | Healthcare |
| Amgen Inc. (AMGN) | $81.93B | Healthcare |
| AstraZeneca PLC (AZN) | $65.36B | Healthcare |
Frequently asked questions
What is Biogen's total liabilities?
- Latest reported total liabilities for Biogen (BIIB) is $11.18B (period ending December 31, 2025).
How has Biogen total liabilities changed year-over-year?
- Biogen (BIIB) total liabilities changed -1.3% year-over-year on the latest annual filing.
What is the long-term growth rate of Biogen total liabilities?
- Biogen (BIIB) total liabilities compound annual growth rate is -4.3% over the most recent 5 years available.
When did Biogen total liabilities hit its highest annual value?
- Biogen total liabilities reached its highest annual value of $13.93B in 2020.
What was Biogen total liabilities in 2024?
- Biogen (BIIB) total liabilities in 2024 was $11.33B.
What was Biogen total liabilities in 2025?
- Biogen (BIIB) total liabilities in 2025 was $11.18B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
BIIB Overview
Company profile, financial tools, and key metrics
BIIB Revenue Counter
Earns $311.09 every second. See per minute, hour, and day.
BIIB Earnings Counter
Earns $41.01 per second net profit. See per minute, hour, and day.
BIIB Economic Scale
Exceeds Bermuda's GDP. Compare with world economies.
BIIB What If Invested
What if you had invested $1,000? See historical returns from any date.
BIIB How It Makes Money
Discover visual breakdown of $9.81B in revenue — where it comes from and where it goes.
BIIB Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
BIIB Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
BIIB Daily Price Character
Explosive · 48.1% historical win rate (green days). Streaks & record days.
BIIB Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.
BIIB Stock Split History
2 splits on record. Dates, ratios, and cumulative multiple.